Prognostic Value of Inflammatory Bowel Disease-associated Biomarkers in Patients With Immune Checkpoint Inhibitor Enterocolitis: A Retrospective Cohort Study

Lawrence Kogan; Matthew J Townsend; Dhanya Raj; Alexander N Levy; Anita Giobbie-Hurder; Shilpa Grover

doi:10.1093/ibd/izad121

Prognostic Value of Inflammatory Bowel Disease-associated Biomarkers in Patients With Immune Checkpoint Inhibitor Enterocolitis: A Retrospective Cohort Study

Inflamm Bowel Dis. 2024 Jun 3;30(6):1032-1035. doi: 10.1093/ibd/izad121.

Authors

Lawrence Kogan¹, Matthew J Townsend², Dhanya Raj³, Alexander N Levy⁴, Anita Giobbie-Hurder⁵, Shilpa Grover^{3

6}

Affiliations

¹ Division of Digestive Diseases, Yale School of Medicine, New Haven, CT, USA.
² Department of Medicine, Duke University Medical Center, Durham, NC, USA.
³ Division of Gastroenterology, Hepatology, and Endoscopy, Brigham & Women's Hospital, Boston, MA, USA.
⁴ Division of Gastroenterology, Tufts Medical Center, Boston, MA, USA.
⁵ Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
⁶ Harvard Medical School, Boston, MA, USA.

PMID: 37421640
DOI: 10.1093/ibd/izad121

No abstract available

Keywords: biologic; biomarker; colitis; immune checkpoint inhibitor; immune-related adverse event.

Plain language summary

In the emerging field of immune checkpoint inhibitor enterocolitis, biomarkers to predict disease course are lacking. Select genetic polymorphisms (ATG16L1T300A) and serum amyloid A warrant further study as potential biomarkers associated with severe ICI enterocolitis.

Publication types

Letter

MeSH terms

Adult
Aged
Biomarkers* / analysis
Enterocolitis* / chemically induced
Female
Humans
Immune Checkpoint Inhibitors* / adverse effects
Immune Checkpoint Inhibitors* / therapeutic use
Inflammatory Bowel Diseases* / drug therapy
Male
Middle Aged
Prognosis
Retrospective Studies

Substances

Immune Checkpoint Inhibitors
Biomarkers